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Dear Editor,
We read with interest the publication by Lamontagne 
et al. [1]. The authors compared the effects of two treat-
ment regimens with different mean arterial blood pres-
sure (MAP) targets on various outcome parameters. In 
addition to the excellent accompanying editorial, we 
would like to emphasize two issues. First, the participat-
ing medical and nursing staff did not follow the objec-
tives of the study and in general maintained a higher 
blood pressure than the actual target in both the low and 
high MAP groups. This required significantly higher dos-
ing of vasopressors in the high-MAP group, resulting in 
adverse effects. This reflects an obvious common bias in 
the treatment of critically ill patients. Generally, physi-
ologic variables in survivors of critical illness are closer 
to normal than those in non-survivors [2], leading to an 
erroneous thinking that maintaining more normal values 
creates survivors. This concept has been proven false in 
many studies and is theoretically flawed [3].
Second, we were surprised that in the discussion the 
use of vasopressors was repeatedly referred to as ‘treat-
ment’ suggesting that vasodilatory shock automati-
cally benefits from vasopressor treatment. For example, 
the authors defend the higher than target MAP in both 
groups: “…which suggests that nurses and physicians 
take great care to avoid under dosing vasopressors…”. 
This suggests that the use of vasopressors should have 
target doses, analogous to dosing antibiotics to reach 
target plasma concentrations. However, in patients with 
MAP considered too low to maintain vital organ perfu-
sion by the treatment team, the aim of therapy is not to 
administer vasopressors but to improve MAP to ade-
quate levels. Various other interventions can be used or 
may be necessary to reach this goal varying from fluid 
resuscitation (or even fluid removal) to the use of vari-
ous types of circulatory assist in the most extreme cases. 
Although this may seem semantic, we think this is con-
ceptually relevant. Rather than using a specific MAP to 
limit the use of vasopressors, vasopressors should be tar-
geted to maintain tissue perfusion. Fixed MAP targets in 
large groups of septic patients, who are inevitably het-
erogeneous, ignore the individual variability in (patho)
physiology of patients and the needs to maintain tis-
sue perfusion. The therapeutic interventions needed to 
maintain tissue perfusion are likely to change during the 
course of the disease. In this context, using fixed MAP 
targets appears simplistic. Rather, the targets should be 
individually adjusted.
The need for high dosages of vasopressors reflects 
severity of illness [4] and should urge the treatment team 
to reconsider the target: the level necessary to achieve 
and maintain sufficient tissue perfusion could even be 
much lower [5] than the ranges achieved in the study by 
Lamontagne et al. [1] and could help to avoid the adverse 
effects of high-dose vasopressors.
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